We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TEZSPIRE AstraZeneca Pty Ltd
Product name
TEZSPIRE
Sponsor
Accepted date
Sep-2025
Active ingredients
tezepelumab
Proposed indication
Tezspire (tezepelumab) is proposed for the treatment in adult patients of chronic rhinosinusitis with nasal polyps, an inflammatory condition affecting the sinuses that is accompanied by nasal polyps—soft, noncancerous growths inside the nose and sinuses.
Application type
C (new indication)
Publication date
Sep-2025